美国放射肿瘤机构参与国家质量改进:骨转移姑息放疗指南依从性
该研究基于CMS Hospital Compare等数据库,分析美国放疗机构对骨转移姑息性体外束放疗(EBRT)质量指标的报告参与情况。4829家医院中2030家具备放疗能力,814家(40%)报告了指南依从性EBRT率,中位依从率为89%,9%的中心依从率低于50%。参与度在地理、教学状态、所有权等因素间差异显著,提示存在质量差距。
要点
- 仅40%具备放疗能力的医院报告了骨转移姑息EBRT质量指标。
- 指南依从性EBRT利用率中位数为89%,但9%的中心低于50%。
- 病例数增加、医院星级和患者体验评分较高与低依从风险降低相关。
核心结论
- 放疗参与国家质量改进尚处早期,骨转移姑息EBRT存在潜在质量差距。
- 需要更稳健的放疗特异性质量指标。
研究设计与样本
- 链接CMS Hospital Compare、IAEA放疗中心目录、2010年美国人口普查和CMS住院前瞻性支付系统数据。
- 纳入4829家医院,其中2030家具备放疗能力,814家报告了骨转移姑息EBRT质量指标。
- 抽样33614例接受EBRT的骨转移合格病例。
主要发现
- 814家(40%)具备放疗能力的医院报告了指南依从性EBRT率。
- 指南依从性姑息EBRT利用率中位数为89%。
- 814家中心中9%的依从率低于50%。
- 参与质量报告在地理、人口类型、教学状态、医院所有权、医院类型和规模间差异显著。
关键数值与推荐
- 指南依从性EBRT利用率中位数为89%。
- 9%的中心依从率低于50%。
临床怎么用
- 放疗科应关注骨转移姑息EBRT的指南依从性,尤其低依从中心。
- 参与国家质量报告有助于识别和缩小质量差距。
局限性
- 原文未明确报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To characterize the participation of radiation oncology (RO) in reporting quality metrics through the Centers for Medicare and Medicaid Services' (CMS) Hospital Compare database and to describe the association of hospital characteristics with RO-specific quality metrics. METHODS AND MATERIALS: Data from the CMS Hospital Compare, International Atomic Energy Agency's Directory of Radiotherapy Centre, 2010 US Census, and CMS Inpatient Prospective Payment System were linked to create an integrated data set of geographic information, facility characteristics, and quality measures, focusing on the use of external beam radiation therapy (EBRT) for bony metastases. RESULTS: Of 4829 hospitals in the Hospital Compare database, 2030 had access to radiation therapy. Among these, 814 (40%) reported on the rate of guideline-concordant EBRT for bony metastases, a RO-specific quality measure. A total of 33,614 eligible cases of bony metastases treated with EBRT were sampled. Participation in quality reporting varied significantly by geography, population type, teaching status, hospital ownership, hospital type, and hospital size. The median rate of guideline-concordant palliative EBRT utilization was 89%. Nine percent of 814 centers had a compliance rate of less than 50%. On multivariable analysis, increasing number of cases sampled (odds ratio 0.93, P = .028), increasing hospital star-rating, and above-average patient experience rating (odds ratio 0.58, P = .024) remained significantly associated with decreased odds of falling into the lowest quartile of guideline-concordant EBRT utilization. CONCLUSIONS: RO participation in a large, national quality improvement effort is nascent and reveals potential quality gaps between hospitals offering palliative EBRT for bone metastases. More robust RO-specific quality measures are needed.
引用
- Dinh TT, Ford E, Halasz LM, et al. National Quality Improvement Participation Among US Radiation Oncology Facilities: Compliance with Guideline-Concordant Palliative Radiation Therapy for Bone Metastases. Int J Radiat Oncol Biol Phys. 2020. PMID: 32407931. doi:10.1016/j.ijrobp.2020.04.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。